RxDoctor Payments Data

Bilal Mahmood, MD

Adult Reconstructive Orthopaedic Surgery · Dallas, TXNPI 1598112013

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (36.6%), education and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Stryker at 34.5% of the total.

$32,562in general payments, 2019–2025

Across 90 payments — averaging $361.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$11K
  • Smith+Nephew$10K
  • Medical Device Business Services, Inc.$7K
  • Synthes GmbH$2K
  • Skeletal Dynamics Inc$723
  • Johnson & Johnson$523
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$11,91037%
  • Speaking & faculty fees$1,5005%
  • Travel & lodging$4,46914%
  • Food & beverage$4,68214%
  • Education$10,00031%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,562 in reported general payments places this provider in the 70th percentile of 86 adult reconstructive orthopaedic surgery providers in Texas.

See all adult reconstructive orthopaedic surgery providers in Texas

Medicare billing

Part B allowed, 2024
$275,202
Medicare patients
498
Services billed
7,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam726$1,801
Ondansetron OdtOndansetron119$1,589
Doxycycline Monohydrate22$1,551
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen153$1,542
Diclofenac Sodium163$1,480
Oxycodone Hcl183$1,269
Omeprazole106$852
Tramadol Hcl226$792
Mupirocin96$727
Methylprednisolone26$211
Amoxicillin32$19

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →